📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-27 17:52
85 analysed today
FollowTelegram
85
Today
153,514
All-time analysed
44,120
Positive
6,818
Negative
93,629
Neutral
8,879
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
Bio Medica Laboratories Shareholders Approve Sale of 51% Stake in Vitamax Pvt Ltd
Bio Medica Laboratories Limited (BMLL) announced the approval of all four postal ballot resolutions by shareholders with 100% of votes cast in favor. The key approval includes a Special Resolution to sell and disinvest the company's 51% equity shareholding in its subsidiary, Vitamax Private Limited. Additionally, shareholders approved higher thresholds for loans, guarantees, and securities under Sections 185 and 186, as well as material related-party transactions under Section 188. Out of 12,575,001 total outstanding equity shares, 10,336,541 shares (82.20% turnout) participated in the remote e-voting.
Confidence: HIGH
What changedShareholders formally approved the divestment of BMLL's 51% equity holding in subsidiary Vitamax Private Limited and cleared enhanced limits for related-party transactions and corporate loans.
Why it mattersThe divestment of the 51% subsidiary stake enables the company to monetize non-core assets or restructure operations, while the expanded loan/investment headroom facilitates future corporate financing.
Subsidiary stake approved for sale: 51%Total shares polled: 10,336,541Turnout percentage: 82.1991%Votes in favor across all resolutions: 100.00%
📅 Short termNeutral; postal ballot outcome formalizes the board's authority to execute the divestment, but final transaction terms remain to be disclosed.
📈 Long termThe structural impact will depend on the final deal consideration, capital redeployment, and balance sheet changes following the subsidiary de-consolidation.
⚠ Risk flags
- Valuation, buyer identity, and sale consideration for Vitamax Private Limited are not yet disclosed
- Material related-party transaction approvals warrant monitoring for governance and arms-length pricing
Key Highlights
100% of votes cast (10,336,541 votes) were in favour of selling the 51% stake in subsidiary Vitamax Private Limited
Overall voting turnout was 82.20% across 18 participating shareholders out of 347 total members
Promoter group polled 8,512,541 votes (99.9957% of promoter holding), all in favour
Shareholders also approved enhanced limits for inter-corporate loans, guarantees, and investments under Sections 185 and 186
👀 What to Watch
Track subsequent regulatory filings disclosing the buyer, transaction valuation, cash consideration, and timeline for the Vitamax Private Limited stake sale.
BMLL to seek approval for 51% subsidiary sale and ₹100 Cr investment limit
Bio Medica Laboratories Limited (BMLL) has initiated a postal ballot to seek shareholder approval for the disinvestment of its 51% stake in subsidiary Vitamax Private Limited. The company is also requesting an increase in its investment and loan limits under Section 186 to ₹100 Crores. Furthermore, it seeks approval for Related Party Transactions (RPT) up to ₹50 Crores for the 2026-27 financial year. The e-voting period for these resolutions runs from July 29, 2026, to August 27, 2026.
Confidence: HIGH
What changedThe company is transitioning from a holding position in Vitamax Private Limited to a potential exit and is significantly expanding its legal headroom for inter-corporate loans and investments.
Why it mattersThe sale of a majority stake in a subsidiary is a material structural change that will impact consolidated financials. The high RPT and investment limits (₹50 Cr and ₹100 Cr respectively) require scrutiny regarding capital allocation and governance.
Subsidiary stake for sale: 51%Section 186 investment limit: ₹100 CroresRPT limit (FY 2026-27): ₹50 CroresE-voting end date: August 27, 2026
📅 Short termThe stock may see volatility as investors react to the disinvestment news; the market will look for the specific sale price of the Vitamax stake.
📈 Long termThe long-term impact depends on how the proceeds from the disinvestment are utilized and whether the ₹100 Cr investment limit is used for value-accretive growth or related-party support.
⚠ Risk flags
- Potential for high-value Related Party Transactions (₹50 Cr)
- Lack of immediate disclosure on the valuation/consideration for the subsidiary sale
- Risk of capital misallocation under the expanded ₹100 Cr investment limit
Key Highlights
Proposal to sell or disinvest 51% equity shareholding in subsidiary Vitamax Private Limited
Request to increase the threshold for loans, guarantees, and investments to ₹100 Crores
Proposed limit for Related Party Transactions set at ₹50 Crores for FY 2026-27
E-voting period scheduled from July 29, 2026, to August 27, 2026
Cut-off date for eligibility to vote was Friday, July 24, 2026
👀 What to Watch
Investors should monitor the company's website for the full explanatory statement to understand the valuation of the Vitamax stake sale and the intended use of the expanded ₹100 Cr investment limit.
BMLL to Sell 51% Stake in Vitamax Pvt Ltd; Seeks ₹100 Cr Investment Limit
Bio Medica Laboratories Limited (BMLL) has initiated a postal ballot to seek shareholder approval for four major resolutions. The primary agenda includes the disinvestment of its 51% equity stake in its subsidiary, Vitamax Private Limited. Additionally, the company is seeking to increase its limit for loans, guarantees, and investments under Section 186 to ₹100 Crores and set a Related Party Transaction (RPT) limit of ₹50 Crores for FY 2026-27. The e-voting period is scheduled from July 29, 2026, to August 27, 2026.
Confidence: HIGH
What changedThe company is seeking authorization to exit a subsidiary and significantly expand its financial limits for inter-corporate loans and related-party dealings.
Why it mattersThe disinvestment will alter the company's consolidated financial structure, while the ₹100 Crore investment limit and ₹50 Crore RPT limit indicate potential significant capital reallocation or group-level financial support.
Subsidiary Stake for Sale: 51%Section 186 Investment Limit: ₹100 CroresRPT Limit (FY 2026-27): ₹50 CroresE-voting End Date: August 27, 2026
📅 Short termThe stock may see volatility as investors react to the potential cash inflow from the subsidiary sale versus the risks associated with higher related-party transaction limits.
📈 Long termThe long-term impact depends on whether the disinvestment proceeds are used for core business growth or diverted through the newly requested ₹100 Crore investment/loan headroom.
⚠ Risk flags
- Related-party transactions (₹50 Cr limit)
- Potential capital diversion via Section 186 limits
- Valuation of subsidiary sale not yet disclosed
Key Highlights
Proposed sale of 51% equity shareholding in subsidiary Vitamax Private Limited.
Request for approval to increase investment and loan limits under Section 186 up to ₹100 Crores.
Proposed limit for Related Party Transactions (RPT) set at ₹50 Crores for the Financial Year 2026-27.
E-voting period commences on July 29, 2026, and concludes on August 27, 2026.
Cut-off date for eligibility to vote was Friday, July 24, 2026.
👀 What to Watch
Investors should monitor the subsequent disclosure regarding the sale consideration for the 51% stake in Vitamax and the specific utilization plan for the proposed ₹100 Crore investment headroom.
BMLL Reports ₹16.25 Cr PBT for FY26; Proposes Subsidiary Disinvestment
Bio Medica Laboratories Limited (BMLL) reported a 23.7% year-on-year increase in consolidated Profit Before Tax to ₹16.25 Cr for FY26. Despite the profit growth, the company's cash flow position remains strained, with Net Cash from Operating Activities worsening to a negative ₹6.03 Cr, largely driven by a significant ₹17.90 Cr increase in inventory. The board has also initiated a postal ballot to seek shareholder approval for the disinvestment of a subsidiary and to increase limits for inter-corporate loans, guarantees, and related party transactions.
Confidence: HIGH
What changedThe company has approved its FY26 audited results and is now seeking shareholder permission to divest a subsidiary and expand its financial limits for loans and guarantees.
Why it mattersWhile the company is growing its bottom line, the persistent negative operating cash flow and rising debt levels to fund inventory are critical financial health indicators that need monitoring.
Net Profit Before Tax (FY26): ₹1625.41 LakhsOperating Cash Flow (FY26): -₹603.46 LakhsInventory Increase: ₹1790.42 LakhsTotal Borrowing Increase: ₹1049.09 LakhsTangible Asset Purchase: ₹281.15 Lakhs
📅 Short termThe market may react to the 23.7% PBT growth, but the negative cash flow and disinvestment news will likely lead to a cautious outlook in the coming weeks.
📈 Long termThe long-term trajectory depends on the company's ability to convert its reported profits into actual cash and the strategic rationale behind selling its subsidiary.
⚠ Risk flags
- Negative operating cash flow for two consecutive years
- High working capital intensity (inventory buildup)
- Proposed material related party transactions
- Increased reliance on debt financing
Key Highlights
Consolidated Profit Before Tax increased to ₹1625.41 Lakhs in FY26 from ₹1314.27 Lakhs in FY25.
Net Cash Flow from Operating Activities was negative ₹603.46 Lakhs, compared to negative ₹457.42 Lakhs in the previous year.
Inventory levels saw a massive outflow of ₹1790.42 Lakhs, indicating significant working capital blockage.
Total borrowings increased by ₹1049.09 Lakhs during the year to fund operations and a ₹281.15 Lakhs capex.
Board proposed a postal ballot for the sale/disinvestment of a subsidiary company and approval of material related party transactions.
👀 What to Watch
Investors should closely examine the upcoming postal ballot notice to understand which subsidiary is being sold and the terms of the proposed material related party transactions.
